Noticias de BMY_US
Noticias del mercado
Últimas noticias sobre BMY_US — 799 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.
Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares’ Cell Shuttle platform could not meet the requirements needed to manufacture Breyanzi at commercial scale. The partnership, announced in 2024, was valued at up to $380 million and was intended to expand Breyanzi manufacturing capacity across the U.S., Europe, […]
Bristol Myers Squibb Company (NYSE:BMY - Get Free Report) SVP Phil Holzer sold 500 shares of the firm
Cytokinetics has filed a legal complaint against Bristol-Myers Squibb (NYSE:BMY) and MyoKardia over patents linked to the heart drug MYQORZO, also known as aficamten. The complaint seeks a declaratory judgment on patent validity and non-infringement related to certain Cytokinetics intellectual property. The dispute introduces an additional source of legal and competitive uncertainty around MYQORZO and related cardiac therapies. For more context on how peers in the same therapeutic area are...
Primecap Management Co. CA purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 24,923,900 shares of the biopharmaceutical company
The Manufacturers Life Insurance Company bought a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,176,661 shares of the biopharmaceutical company
Canada Pension Plan Investment Board acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 4,186,444 shares of the biopharmaceutical company
Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its partnership with the manufacturing specialist.
Miller Value Partners LLC acquired a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 69,500 shares of the biopharmaceutical company
EFG International AG purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 79,256 shares of the biopharmaceutical company
Manning & Napier Advisors LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 184,742 shares of the biopharmaceutical comp
OMERS ADMINISTRATION Corp acquired a new position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 173,350 shares of the biopharma
Legal & General Group Plc acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 17,022,940 shares of the biopharmaceutical company
Página 6 de 40